Lowery, Caitlin D <br/><br/>
Olaratumab Exerts Antitumor Activity in Preclinical Models of Pediatric Bone and Soft Tissue Tumors through Inhibition of Platelet-Derived Growth Factor Receptor α.  [electronic resource] 

 -  Clinical cancer research : an official journal of the American Association for Cancer Research  02 2018 
 - 847-857 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1557-3265 
<br/><br/><label>Standard No.: </label>10.1158/1078-0432.CCR-17-1258  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Antibodies, Monoclonal--administration & dosage<br/>Antineoplastic Combined Chemotherapy Protocols--pharmacology<br/>Cell Line<br/>Cell Line, Tumor<br/>Child<br/>Disease-Free Survival<br/>Humans<br/>Mice, Nude<br/>Receptor, Platelet-Derived Growth Factor alpha--antagonists & inhibitors<br/>Sarcoma--drug therapy<br/>Soft Tissue Neoplasms--drug therapy<br/>Tumor Burden--drug effects<br/>Xenograft Model Antitumor Assays